Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer

Fig. 1

Effects of combinatorial treatments on human MDA-MB-231 cells in the absence or presence of lymphocytes. a Cell growth inhibition of MDA-MB-231 cells, untreated or treated with the anti-PD-L1 (10_12) mAb or the PDGFRβ aptamer, used alone (dark grey bars) or in combination (black bars), for 96 h at 37 °C at the indicated concentrations. Untreated cells (white bars) or cells treated with an unrelated IgG or Scr (light grey bars) were used as negative controls. Data were expressed as percentage of viable treated cells with respect to untreated cells. b-e MDA-MB-231 cells were co-cultured with human lymphocytes and left untreated or treated for 24 h, as indicated. b Cell counts were expressed as percentage of viable treated cells with respect to untreated co-cultured cells. c Cell lysis was expressed as measure of LDH release and reported as percentage of lysis of treated cells with respect to the untreated cells, used as a control. d IL-2 and e IFN-γ secretion levels were measured by ELISA on supernatants of cells treated, as indicated. a-e Error bars depict mean ± SD (n = 3). ####P < 0.0001, ### P < 0.001, ## P < 0.01 relative to IgG; °P < 0.05 relative to Scr; ****P < 0.0001, *** P < 0.001, ** P < 0.01, *P < 0.05; one-way ANOVA followed by Tukey’s multiple comparison test

Back to article page